Interpace Diagnostics

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50%, prime being the greater of the bank's stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5% per annum. The Bank will have a first priority security interest in substantially all of Interpace's and its subsidiaries' assets and will be senior to the existing $7.5 Million bridge loans made by the Company's private equity investors.

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer a new capability in providing Digital Spatial Profiling services using the novel GeoMx® testing platform. GeoMx® combines the benefits of IHC/FISH and high-throughput expression analysis into one streamlined tissue multiplexing assay. Protein and nucleic acids can now be measured by Interpace with an unparalleled level of precision, from whole tissue to single cell, in either an FFPE sample or frozen tissue section.

Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology (CPT®) code set approved by the American Medical Association CPT® Editorial Panel. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs that want to more specifically identify their test. The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimbursement level of $560. In December, 2020, Novitas issued a new local coverage determination (LCD) for ThyGeNEXT® that reflects the test's enhanced mutation panel. In 2020, Interpace processed approximately 15,000 ThyGeNEXT® tests for over 700 physicians.

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

Part of Company's Site Consolidation and Cost Savings Measures

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of the Company's common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on February 25, 2021 under the symbol IDXG. The Company previously traded on Nasdaq.

Interpace Biosciences Announces Acceptance for Trading on the OTCQX

PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff has determined to delist the Company's securities from Nasdaq. This determination was due to the Company's extended period of non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing set forth in listing Rule 5550(b) and the Company's failure to timely execute on its plan to comply. Unless the Company requests an appeal of this determination, trading of the Company's common stock will be suspended at the opening of business on February 25, 2021. The Company has applied to have its common stock qualified to trade on the OTCQX® Best Market (“OTCQX”).

Interpace Biosciences Announces Impending Delisting from Nasdaq

PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders:

Interpace Biosciences Announces Path Forward in Letter to Shareholders

PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace's Chief Financial Officer (“CFO”). Mr. Freeburg succeeds Fred Knechtel effective February 1, 2021.

Interpace Biosciences Announces CFO Leadership Transition

Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cysts, the Das-1 antibody was able to accurately identify pancreatic cysts likely to become cancerous with high sensitivity and high specificity in comparison to current clinical guidelines (Das, K et al, “Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesion”, (Gastroenterology 2019; 157:720-730). Das-1 is gaining recognition among experts in the GI community as evidenced by its inclusion as a component in the Pancreatic Cyst Biomarker Alliance sponsored in part by the National Cancer Institute.

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida

PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET.

Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021

Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET

Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by Thomas Burnell, PhD., effective December 1, 2020. Mr. Stover, who will step down from the Interpace Board of Directors once Dr. Burnell joins the company and is appointed to the Board, will serve as an advisor to the company through the middle of 2021 in order to support the transition.

Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor

PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the delay in the filing of the Company's Form 10-Q for the quarterly period ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), Interpace does not currently satisfy Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of all periodic reports with the SEC. The deficiency has no immediate effect on the listing or trading of the Company's common stock on Nasdaq.

Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing

 Study Demonstrates Superior Performance of ThyGeNEXT ® and ThyraMIR ® vs. Other Molecular Tests

Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays

Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million

Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results

Interpace Biosciences (IDXG) news for Wednesday includes a positive audit committee result giving IDXG stock a much-needed boost. The post Interpace Biosciences News: Why IDXG Stock Is Soaring 48% Today appeared first on InvestorPlace.

Interpace Biosciences News: Why IDXG Stock Is Soaring 48% Today

PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has completed an independent investigation into complaints of certain employment and billing and compliance matters and concluded that the allegations made in the complaints are unsubstantiated and that there was no evidence of any illegal acts.

News for Interpace Diagnostics Stock (IDXG)